Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $139,451.22 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Todd Watanabe sold 4,377 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $31.86, for a total transaction of $139,451.22. Following the transaction, the insider owned 712,826 shares of the company’s stock, valued at $22,710,636.36. This represents a 0.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arcutis Biotherapeutics Trading Down 5.4%

Shares of NASDAQ ARQT opened at $25.55 on Friday. The stock has a market cap of $3.21 billion, a price-to-earnings ratio of 121.67 and a beta of 1.66. The company’s fifty day moving average is $27.16 and its 200-day moving average is $25.37. Arcutis Biotherapeutics, Inc. has a twelve month low of $19.30 and a twelve month high of $34.80. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 0.46.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.12). The company had revenue of $143.92 million during the quarter, compared to the consensus estimate of $142.59 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. Equities research analysts predict that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current year.

Institutional Trading of Arcutis Biotherapeutics

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Arcutis Biotherapeutics in the 2nd quarter valued at about $276,502,000. Bank of America Corp DE acquired a new position in Arcutis Biotherapeutics in the second quarter valued at approximately $78,330,000. Jupiter Topco LLC acquired a new stake in Arcutis Biotherapeutics during the second quarter worth approximately $36,989,000. Bamco Inc. NY acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at about $32,857,000. Finally, Simplify Asset Management Inc. bought a new position in shares of Arcutis Biotherapeutics during the 3rd quarter worth $22,885,000.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Analysts Set New Price Targets

ARQT has been the topic of a number of research analyst reports. Cantor Fitzgerald started coverage on Arcutis Biotherapeutics in a report on Thursday, October 15th. They set an “overweight” rating and a $48.00 price target on the stock. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 29th. Wall Street Zen lowered Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. TD Cowen lifted their target price on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Morgan Stanley upped their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $39.75.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.